Clinical trials
Phase 2 Endometrial Neoplasms trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 6 |
| Active, not recruiting | 4 |
| Terminated | 2 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gynecologic Oncology Group | 5 |
| National Cancer Institute (NCI) | 3 |
| Merck Sharp & Dohme LLC | 2 |
| NCIC Clinical Trials Group | 2 |
| AstraZeneca | 1 |
| Bayer | 1 |
| CASI pharmaceuticals, Inc. | 1 |
| Canadian Cancer Trials Group | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Daiichi Sankyo | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Endometrial Neoplasms | 32 |
| Ovarian Neoplasms | 6 |
| Uterine Cervical Neoplasms | 6 |
| Stomach Neoplasms | 4 |
| Esophageal Neoplasms | 3 |
| Neoplasms | 3 |
| Sarcoma | 3 |
| Urinary Bladder Neoplasms | 3 |
| Uterine Neoplasms | 3 |
| Biliary Tract Neoplasms | 2 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.